Generation Bio Co (GBIO) - Total Liabilities
Based on the latest financial reports, Generation Bio Co (GBIO) has total liabilities worth $71.34 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GBIO year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Generation Bio Co - Total Liabilities Trend (2018–2024)
This chart illustrates how Generation Bio Co's total liabilities have evolved over time, based on quarterly financial data. See GBIO free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Generation Bio Co Competitors by Total Liabilities
The table below lists competitors of Generation Bio Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lotte Chilsung Beverage Co Ltd
KO:005305
|
Korea | ₩2.68 Trillion |
|
Sheh Kai Precision Co Ltd
TWO:2063
|
Taiwan | NT$1.05 Billion |
|
Yuanta Securities Korea Co Ltd Preference Shares
KO:003475
|
Korea | ₩20.33 Trillion |
|
Beaconsmind AG
PA:MLBMD
|
France | €1.90 Million |
|
Boer Power Holdings Limited
F:BOE
|
Germany | €1.25 Billion |
|
Estrella Resources Ltd
AU:ESR
|
Australia | AU$680.72K |
|
Dynamic Precision Industry
TWO:8928
|
Taiwan | NT$2.54 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Generation Bio Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GBIO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Generation Bio Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Generation Bio Co (2018–2024)
The table below shows the annual total liabilities of Generation Bio Co from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $144.99 Million | -15.52% |
| 2023-12-31 | $171.63 Million | +83.03% |
| 2022-12-31 | $93.77 Million | -1.32% |
| 2021-12-31 | $95.03 Million | +263.50% |
| 2020-12-31 | $26.14 Million | -81.42% |
| 2019-12-31 | $140.73 Million | +12.49% |
| 2018-12-31 | $125.11 Million | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more